Sanofi (NASDAQ:SNY) Shares Acquired by Signaturefd LLC

Signaturefd LLC increased its stake in shares of Sanofi (NASDAQ:SNY) by 2.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 38,200 shares of the company’s stock after acquiring an additional 853 shares during the period. Signaturefd LLC’s holdings in Sanofi were worth $1,842,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of the stock. Envestnet Portfolio Solutions Inc. grew its stake in shares of Sanofi by 0.5% during the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 112,181 shares of the company’s stock worth $5,411,000 after purchasing an additional 578 shares during the period. Natixis Advisors LLC boosted its holdings in Sanofi by 1.2% during the fourth quarter. Natixis Advisors LLC now owns 2,910,021 shares of the company’s stock worth $140,350,000 after buying an additional 35,828 shares in the last quarter. Brandes Investment Partners LP grew its position in Sanofi by 3.6% during the fourth quarter. Brandes Investment Partners LP now owns 2,194,938 shares of the company’s stock valued at $105,862,000 after buying an additional 76,092 shares during the period. Aviso Financial Inc. increased its holdings in Sanofi by 1.1% in the fourth quarter. Aviso Financial Inc. now owns 41,837 shares of the company’s stock valued at $2,018,000 after buying an additional 457 shares in the last quarter. Finally, JPL Wealth Management LLC purchased a new position in Sanofi in the fourth quarter valued at $2,277,000. 14.04% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms have recently commented on SNY. Deutsche Bank Aktiengesellschaft upgraded Sanofi from a “sell” rating to a “hold” rating in a research report on Thursday, January 30th. StockNews.com cut Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. Finally, Sanford C. Bernstein upgraded Sanofi to a “strong-buy” rating in a research report on Thursday, January 30th. Two equities research analysts have rated the stock with a hold rating, one has given a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $60.00.

Sanofi Stock Up 2.0 %

SNY opened at $58.92 on Tuesday. The company has a market cap of $149.53 billion, a PE ratio of 23.66, a price-to-earnings-growth ratio of 1.01 and a beta of 0.58. Sanofi has a twelve month low of $45.22 and a twelve month high of $60.12. The company has a 50-day moving average price of $53.85 and a 200 day moving average price of $52.83. The company has a quick ratio of 1.14, a current ratio of 1.46 and a debt-to-equity ratio of 0.15.

Sanofi (NASDAQ:SNY) last announced its earnings results on Thursday, January 30th. The company reported $0.70 EPS for the quarter, meeting analysts’ consensus estimates of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. Sell-side analysts expect that Sanofi will post 4.36 earnings per share for the current fiscal year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.